

**Remarks:**

Claim 15 has been amended to replace the term "said compound" with the term "said medicament." Applicant believes that the amendment obviates the rejection under 35 U.S.C. §112, second paragraph, as the term "said medicament" has antecedent basis.

Claim 15 is rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-13 of U.S. Patent No. 6,759,426, to which the instant application claims priority. Applicant has enclosed herewith a terminal disclaimer in compliance with 37 C.F.R. §1.321(c).

**Conclusion:**

In view of the above claim amendments and remarks, Applicant respectfully requests reconsideration and withdrawal of all objections and rejections.

Respectfully submitted,



Daniel S. Kasten  
Agent for Applicants  
Reg. No. 45,363  
314-274-5218

Pfizer Inc  
Corporate Patent Law Department  
P.O. Box 1027  
Chesterfield, Missouri 63006